Essential Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Essential Partners’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$49	Sell	2 -51	-96%	-$1.41K	﹤0.01%	2771
2026 Q2	$1.8K	Buy	53 +51	+2,550%	+$1.68K	﹤0.01%	2013
2026 Q1	$64	Hold	2	–	–	﹤0.01%	2771
2025 Q4	$70	Hold	2	–	–	﹤0.01%	2607
2025 Q3	$57	Hold	2	–	–	﹤0.01%	2555
2025 Q2	$36	Buy	+2	New	+$36	﹤0.01%	2182

Other funds holding NAMS

TSMHT

Thurston Springer Miller Herd & Titak Indianapolis, Indiana $61.1M AUM 22.51% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's NAMS Position: Q3 2026 in Review

Essential Partners reduced its NewAmsterdam Pharma (NAMS) stake by 96% in Q3 2026, selling an estimated $1.41K and leaving 2 shares worth $49. The position accounts for ﹤0.01% of the portfolio, ranked #2771.

Essential Partners first reported a position in NAMS in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.8K in Q2 2026. 4 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

Essential Partners held 2 shares of NewAmsterdam Pharma worth $49 as of Q3 2026.
Essential Partners sold 51 NewAmsterdam Pharma shares in Q3 2026, an estimated $1.41K.
NewAmsterdam Pharma made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2771 holding.
Essential Partners first reported a position in NewAmsterdam Pharma in Q2 2025 and has held it in 6 quarters since.
Essential Partners's NewAmsterdam Pharma position peaked at $1.8K in Q2 2026.
4 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.